Intrahepatic periportal high intensity on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI: imaging findings and prevalence in various hepatobiliary diseases.
OBJECTIVE
To reveal the incidence and degree of intrahepatic periportal high intensity (PHI) on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (EOB-MRI) in patients with or without various hepatobiliary diseases.


METHODS
Patients with normal liver (N = 256) and those with hepatic disorder (N = 857) who underwent EOB-MRI were the subjects in this study. Incidence of PHI was evaluated among the patients with normal liver and those with hepatic disorder. Degree of PHI was categorized into four grades and compared among the various hepatic diseases. Enhancement ratios (ER) of the PHI area, background liver with PHI, and background liver in control cases without PHI were evaluated.


RESULTS
PHI was observed in 2.7 % of the patients with hepatic disorder. No PHI was observed in the patients with normal liver. The incidence rates of PHI among various hepatobiliary diseases were as follows; liver cirrhosis 3.1 %, chronic hepatitis 1.0 %, primary biliary cirrhosis 12.5 %, idiopathic portal hypertension 33.3 %. The ER of the PHI area and background liver were 3.92 and 2.48 (p = 0.0002). There were no significant differences between the ER of the PHI area and the ER of background liver in the noncirrhotic control without PHI.


CONCLUSIONS
In 2.7 % of the patients with a hepatic disorder, the periportal area was saved from decrease of EOB uptake and it showed PHI.
Department of Quantum Medical Technology, Kanazawa University School of Medicine, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan. satoshik@staff.kanazawa-u.ac.jp
Satoshi
S
Kobayashi
Osamu
O
Matsui
Toshifumi
T
Gabata
Wataru
W
Koda
Tetsuya
T
Minami
Kazuto
K
Kozaka
Azusa
A
Kitao
Norihide
N
Yoneda
Kotaro
K
Yoshida
D000368:Aged; D016009:Chi-Square Distribution; D003287:Contrast Media / Q000493:pharmacokinetics; D005260:Female; D019786:Gadolinium DTPA / Q000493:pharmacokinetics; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D021621:Imaging, Three-Dimensional; D015994:Incidence; D008107:Liver Diseases / Q000175:diagnosis*; D008111:Liver Function Tests; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D015995:Prevalence; D012189:Retrospective Studies
D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA